References
- United States Food and Drug Administration. Guidance for industry ANDA submissions — content and format of abbreviated new drug applications, ed. Rockville, USA; 2014. p. 3.
- National Pharmaceutical Control Bureau Malaysia, Drug registration guidance document. First ed. Selangor Darul Ehsan, Malaysia National Pharmaceutical Control Bureau Ministry of Health, Malaysia. 2014. https://www.pmda.go.jp/files/000204339.pdf. Accessed 15 Dec 2016.
- World Health Organization. Guidelines on submission of documentation for a multisource (generic) finished product: general format: preparation of product dossiers in common technical document format. In: WHO expert committee on specifications for pharmaceutical preparations. Annex 5 (WHO technical report series, No. 961); 2011.
- European Medicines Agency. Guideline on the investigation of bioequivalence secondary guideline on the investigation of bioequivalence. 2010. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/01/WC500070039.pdf. Accessed 15 June 2015.
- Polli JE. In vitro studies are sometimes better than conventional human pharmacokinetic in vivo studies in assessing bioequivalence of immediate-release solid oral dosage forms. AAPS J. 2008;10(2):289-99.
- United States Food and Drug Administration. Guidance for industry: waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. Rockville, USA; 2015.
- Health Canada. Guidance document: biopharmaceutics classification system based biowaiver. Ottawa: Health Products and Food Branch, Health Canada; 2014. p. 12.
- Health Sciences Authority Singapore. Guidance on medicinal product registration in Singapore. 2011. http://www.hsa.gov.sg/content/hsa/en.html. Accessed 1 June 2015.
- Hill S, Johnson K. Emerging challenges and opportunities in drug registration and regulation in developing countries. Access to medicines. London: Fretwells Ltd; 2004. p. 47.
- Cosmetics Devices and Drug Regulatory Authority. Legislation: National Medicines Regulatory Authority Act, no. 5 of 2015 Colombo, Sri Lanka; 2016. p. 98.
- Fund TG. Quality assurance policy for pharmaceutical products. 2018. https://www.theglobalfund.org/media/5894/psm_qapharm_policy_en.pdf. Accessed 15 Feb 2018.
- Thambawita D, Mannapperuma U, Galappatthy P, Dissanayeke S, Benaragama BVSH, Jayakody RL. Compliance of selected drug dossiers submitted for registration, as per drug regulatory authority requirements and WHO recommendations. Proceedings of international medical congress, Sri Lanka medical association 2015.
- Wharf C. EMA procedural advice for users of the centralised procedure for generic/hybrid applications. 2016. http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2009/10/WC500004018.pdf. Accessed 2 Dec 2016.
- United States Food and Drug Administration. What are generic drugs?. 2015. https://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/GenericDrugs/default.htm. Accesssed 01 July 2016.
- European Medicines Agency. Generic medicines. 2012. http://www.ema.europa.eu/ema/index.jsp?curl=pages/special_topics/document_listing/document_listing_000335.jsp&mid=WC0b01ac0580514d5c. Accessed 15 July 2016.
- Ministry of Health Malaysia. Guidance on Biopharmaceutics Classification System (BCS) based biowaiver. Malaysia: Ministry of Health Malaysia; 2013.
- Pharmaceuticals and Medical Devices Agency Japan. Approval review of generic drugs in Japan. Second international generic drug regulators meeting. 2012. College Park, MD.
- Ministry of Food and Drug Safety Republic of Korea. Approval process. 2016. https://www.mfds.go.kr/eng/index.do?nMenuCode=126. Accessed 10 July 2016.
- Therapeutic Goods Administartion, Australia. Australian regulatory guideline for over-the-counter medicines. 2012. https://www.tga.gov.au/publication/australian-regulatory-guidelines-otc-medicines-argom. Accessed 2 Oct 2016.
- Therapeutic Goods Administration. Common Technical Document (CTD). 2014. https://www.tga.gov.au/publication/common-technical-document-ctd. Accessed 2 Oct 2016.
- Health Canada. Draft guidance for industry:preparation of comparative bioavailability information for drug submissions in the CTD format. 2011. http://www.hc-sc.gc.ca/dhp-mps/prodpharma/applic-demande/guide-ld/ctd/draft_ebauche_ctdbe-eng.php. Accessed 11 June 2016.
- Health Canada. Release of Health Canada’s revisions to “1.6 electronic review documents” in draft guidance for industry: preparation of new drug submissions in the CTD format. 2008. http://www.hc-sc.gc.ca/dhp-mps/prodpharma/applic-demande/guide-ld/ctd/notice_avis_ctd-eng.php. Accessed 15 June 2016.
- European Medicines Agency. ICH topic M 4, common technical document for the registration of pharmaceuticals for human use –organisation CTD secondary ICH topic M 4, common technical document for the registration of pharmaceuticals for human use –organisation CTD. 2004. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002721.pdf. Accessed 15 June 2016.
- Central Drugs Standards Control Organization, India. Guidance for industry on submission of clinical trial application for evaluating safety and efficacy. In: Ministry of Health; 2005. p. 180.
- Central Drugs Standard Control Organization India. Guidance for industry on preparation of common technical document for import/manufacture and marketing approval. New Delhi: Ministry of Health & Family Welfare Govt. of India; 2010. p. 110.
- Pharmaceutical Medical Devices Agency Japan. CH-M4 CTD (common technical document). 2015. https://www.pmda.go.jp/int-activities/int-harmony/ich/0035.html. Accessed 10 Oct 2016.
- United States Food and Drug Administration. Guidance for industry: M4: organization of the CTD.2015. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm073257.pdf. Accessed 10 Oct 2016.
- Ministry of Food and Drug Safety Republic of Korea. Guide to drug approval system in Korea. 2017. http://www.masung.co.kr/bbs/board.php?bo_table=s03_01_eng&wr_id=1. Accessed 10 June 2017.
- National Pharmaceutical Bureau Ministry of Health Malaysia. Generic products containing drug substances/active pharmaceutical ingredients (api) that may be considered for biowaiver. 2014. http://npra.moh.gov.my/images/Guidelines_Central/Guidelines_on_Bioequivalence_BE/Guidance-on-BCS-Based-Biowaiver.pdf. Accessed 7 June 2016.
- Health Sciences Authority in Singapore. Guidance on medicinal product registration in Singapore. 2011. http://www.hsa.gov.sg/content/dam/HSA/HPRG/Western_Medicine/Overview_Framework_Policies/Guidelines_on_Drug_Registration/Updates%20for%20Guidance%20on%20Medicinal%20Product%20Regist. Accessed 15 June 2016.
- Cosmetics Devices and Drugs Regulatory Authorty. Application Forms. Secondary Application Forms. http://nmra.gov.lk/index.php?option=com_content&view=article&id=86&Itemid=84&lang=en. Accessed 5 May 2014.
- Thambavita D, Galappatthy P, Jayakody R. Requirement for bioequivalence and biowaiver data for regulatory decision making: a comparative study of regulatory authorities. Proceeding of the annual scientific session of the Sri Lanka Association of Clinical Pharmacology and Therapeutics Colombo, Sri Lanka: Sri Lanka Association of Clinical Pharmacology and Therapeutics. 2016. p. 24.
- Melchior R. How transparent are regulatory agencies with regard to review timelines? A global review. Chicago: Thomson Reuters France; 2011.
- United States Food and Drug Administration. FDA/GPhA quarterly meeting on GDUFA. 2015. http://www.fda.gov/downloads/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/abbreviatednewdrugapplicationandagenerics/ucm442070.pdf. Accessed 7 June 2016.
- Kuribayashi R, Matsuhama M, Mikami K. Regulation of generic drugs in Japan: the current situation and future prospects. AAPS J. 2015;17(5):1312-6.
- The International Council on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Quality guidelines. 2015. http://www.ich.org/products/guidelines/quality/article/quality-guidelines.html. Accessed 10 Nov 2016.
- World Health Organization. The impact of implementation of ICH guidelines in non-ICH countries. 2001. apps.who.int/medicinedocs/pdf/h2993e/h2993e.pdf. Accessed 2 Oct 2016.
- Ratanawijitrasin S, Wondemagegnehu E. Effective drug regulation a multicountry study. Geneva: World Health Organization; 2002. p. 187.
- Martin H. Harmonization and standardization of the ASEAN medical industry. Council, US-ASEAN business; 2010. p. 75.
- World Health Organization. Marketing authorization of pharmaceutical products with special reference to multisource (generic) products: a manual for drug regulatory authorities. 2 ed. Geneva Switzerland; 2011. p. 148.
- Davit BM, Kanfer I, Tsang YC, et al. BCS biowaivers: similarities and differences among EMA, FDA, and WHO requirements. AAPS J. 2016;18(3):612-8.
- European Medicines Agency. Guideline on quality of oral modified release products. 2016. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/07/WC500170465.pdf. Accessed 10 Oct 2016.
- Kashyap UN, Gupta V, Raghunandan H. Comparison of drug approval process in United States & Europe. J Pharm Sci Res. 2013;5(6):131-6.
- Hirako M, McAuslane N, Salek S, et al. A comparison of the drug review process at five international regulatory agencies. Drug Inf J. 2007;41(3):291-308.
- Galappatthy P, Mythily S, Wickramarathna TN, et al. Availability, prices and registration status of the most commonly prescribed medicines in private pharmacies in Sri Lanka: an island wide survey. Proceedings of the Sri Lanka Association of Clinical Pharmacology and Therapeutics, vol. 31. Colombo: Sri Lanka Association of Clinical Pharmacology and Therapeutics; 2016.
- The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use. Note for guidance on the investigation of bioavailability and bioequivalence. 2001. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003008.pdf. Accessed 10 Oct 2016.
- United States Food and Drug Administration. Guidance for industry- waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. 2000. https://www.fda.gov/downloads/Drugs/Guidances/ucm070246.pdf. Accessed 20 Sept 2016.
- United States Food and Drug Administration. CFR-code of Federal Regulations-Bioavailability and bioequivalence requirements. 2013. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=320&showFR=1&subpartNode=21:5.0.1.1.7.2. Accesed 20 Sept 2016.
- Anand K, Mallu UR, Kuraku M, et al. Pharmaceutical drug products approval procedure in Australia. Exp. 2013;11(3):690-705.
- Health Canada. Guidance for industry-Management of Drug Submissions. In: Therapeutic products directorate. Ontario: Minister of Public Works and Government Services Canada; 2013. p. 46.
- Agency EM. The centralised procedure at the EMA. Secondary the centralised procedure at the EMA. 2016. http://www.ema.europa.eu/docs/en_GB/document_library/Presentation/2016/02/WC500201043.pdf.
- Pacific Bridge Medical. Pharmaceutical and API product registration in the other Asian countries. 2016. http://www.pacificbridgemedical.com/regulatory-services/pharmaceutical/product-registration/others/. Accessed 5 Dec 2016.
- Central Drugs Standards Control Organization, India. CDSCO Timelines. 2014. http://www.cdsco.nic.in//writereaddata/upTimeline%20CDSCO.pdf.